Early identification of interferon-beta responders by ex vivo testing in patients with multiple sclerosis

Clinical Immunology

Volumn 128, Issue 3, 2008, Pages 306-313

  Wiesemann, Elke ^a   Deb, Milani ^a   Hemmer, Bernhard ^b   Radeke, Heinfried H ^c   Windhagen, Anja ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

Co signaling molecules; Cytokines; IFN ; IL 10; Multiple sclerosis; Paraclinical markers

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; CD40 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; INTERFERON BETA SERINE; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5;

ADULT; ARTICLE; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; ANTIGENS, CD; ANTIGENS, CD40; ANTIGENS, CD86; CYTOKINES; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERFERON-BETA; INTERLEUKIN-10; MALE; MIDDLE AGED; MONOCYTES; MULTIPLE SCLEROSIS; UP-REGULATION;

EID: 49149116386     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2008.04.007     Document Type: Article

References (27)

1. Sospedra M., and Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23 (2005) 683-747
2. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 352 (1998) 1498-1504
3. Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M., Fischer J.S., Goodkin D.E., Granger C.V., Simon J.H., Alam J.J., Bartoszak D.M., Bourdette D.N., Braiman J., Brownscheidle C.M., Coats M.E., Cohan S.L., Dougherty D.S., Kinkel R.P., Mass M.K., Munschauer III F.E., Priore R.L., Pullicino P.M., Scherokman B.J., and Whitham R.H. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. 39 (1996) 285-294
4. Paty D.W., and Li D.K. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. 1993 [classical article]. Neurology 57 (2001) S10-S15
5. Hartung H.P., Bar-Or A., and Zoukos Y. What do we know about the mechanism of action of disease-modifying treatments in MS?. J. Neurol. 251 Suppl 5 (2004) v12-v29
6. Bartosik-Psujek H., and Stelmasiak Z. The interleukin-10 levels as a potential indicator of positive response to interferon beta treatment of multiple sclerosis patients. Clin. Neurol. Neurosurg. 108 (2006) 644-647
7. Laske C., Oschmann P., Tofighi J., Kuhne B.S., Diehl H., Bregenzer T., Kraus J., Chatzimanolis N., Bauer R., Traupe H., and Kaps M. Prognostic value of soluble tumor necrosis factor receptors 1 and 2 in multiple sclerosis patients treated with interferon beta-1b. Eur. Neurol. 46 (2001) 210-214
8. Rudick R.A., Ransohoff R.M., Lee J.C., Peppler R., Yu M., Mathisen P.M., and Tuohy V.K. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology 50 (1998) 1294-1300
9. Sturzebecher S., Wandinger K.P., Rosenwald A., Sathyamoorthy M., Tzou A., Mattar P., Frank J.A., Staudt L., Martin R., and McFarland H.F. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain 126 (2003) 1419-1429
10. Wandinger K.P., Lunemann J.D., Wengert O., Bellmann-Strobl J., Aktas O., Weber A., Grundstrom E., Ehrlich S., Wernecke K.D., Volk H.D., and Zipp F. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 361 (2003) 2036-2043
11. Wergeland S., Beiske A., Nyland H., Hovdal H., Jensen D., Larsen J.P., Maroy T.H., Smievoll A.I., Vedeler C.A., and Myhr K.M. IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis. Eur. J. Neurol. 12 (2005) 171-175
12. Wiesemann E., Deb M., Trebst C., Hemmer B., Stangel M., and Windhagen A. Effects of interferon-{beta} on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon-{beta} treatment in patients with multiple sclerosis. Mult. Scler. 14 (2008) 166-176
13. Dong H., Zhu G., Tamada K., and Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. (1999) 1365-1369
14. Marckmann S., Wiesemann E., Hilse R., Trebst C., Stangel M., and Windhagen A. Interferon-beta up-regulates the expression of co-stimulatory molecules CD80, CD86 and CD40 on monocytes: significance for treatment of multiple sclerosis. Clin. Exp. Immunol. 138 (2004) 499-506
15. Wiesemann E., Sonmez D., Heidenreich F., and Windhagen A. Interferon-beta increases the stimulatory capacity of monocyte-derived dendritic cells to induce IL-13, IL-5 and IL-10 in autologous T-cells. J. Neuroimmunol. 123 (2002) 160-169
16. Behrens F., Himsel A., Rehart S., Stanczyk J., Beutel B., Zimmermann S.Y., Koehl U., Möller B., Gay S., Kaltwasser J.P., Pfeilschifter J.M., and Radeke H.H. Imbalance in distribution of functional autologous regulatory T cells in rheumatoid arthritis. Ann. Rheum. Dis. 66 (2007) 1151-1156
17. Hartung H.P., Bar-Or A., and Zoukos Y. What do we know about the mechanism of action of disease-modifying treatments in MS?. J. Neurol. 251 Suppl. 5 (2004) v12-v29
18. Byrnes A.A., McArthur J.C., and Karp C.L. Interferon-beta therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production. Ann. Neurol. 51 (2002) 165-174
19. Rudick R.A., Ransohoff R.M., Lee J.C., Peppler R., Yu M., Mathisen P.M., and Tuohy V.K. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology 50 (1998) 1294-1300
20. Mirowska D., Skierski J., Paz A., Koronkiewicz M., Zaborski J., Kruszewska J., Czlonkowski A., and Czlonkowska A. Changes of percentages in immune cells phenotypes and cytokines production during two-year IFN-beta-1a treatment in multiple sclerosis patients. J. Neurol. 250 (2003) 1229-1236
21. Hemmer B., Stuve O., Kieseier B., Schellekens H., and Hartung H.P. Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurol. 4 (2005) 403-412
22. Haller O., Stertz S., and Kochs G. The Mx GTPase family of interferon-induced antiviral proteins. Microbes Infect. 9 (2007) 1636-1643
23. Gilli F., Marnetto F., Caldano M., Sala A., Malucchi S., Capobianco M., and Bertolotto A. Biological markers if IFN-β therapy: comparison among IFN-stimulated genes MxA, TRAIL and XAF-1. Mult. Scler. 12 (2006) 47-57
24. Río J., Nos C., Tinotré M., Téllez N., Galán I., Pelayo R., Comabella M., and Montalban X. Defining the response to IFN-β in relapsing-remitting multiple sclerosis patients. Ann. Neurol. 59 (2006) 344-352
25. Villoslada P., Oksenberg J.R., Río J., Montalban X., Waubant E.L., Vukusic S., and Confavreux C. Clinical characteristics of response to interferon therapy for relapsing MS. Neurology 62 (2004) 1653
26. R. A. Rudick, J. Lee, J. Simon, M. R. Ransohoff, E. Fisher, Defining Interferon β response status in multiple sclerosis patients.
27. Portaccio E., Zipoli V., Siracusa G., Sorbi S., and Amato M.P. Response to interferon-beta therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria. Mult. Scler. 12 (2006) 281-286